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Vaccination with papillomavirus L2 has been shown to induce neutralizing antibodies that protect against homologous type infection and
cross-neutralize a limited number of genital HPVs. Surprisingly, we found that antibodies to bovine papillomavirus (BPV1) L2 amino acids
1–88 induced similar titers of neutralizing antibodies against Human papillomavirus (HPV)16 and 18 and BPV1 pseudoviruses and also
neutralized HPV11 native virions. These antibodies also neutralized each of the other pseudovirus types tested, HPV31, HPV6 and Cottontail
rabbit papillomavirus (CRPV) pseudoviruses, albeit with lower titers. HPV16, HPV18, HPV31, HPV6 and CRPV L2 anti-sera also displayed
some cross-neutralization, but the titers were lower and did not encompass all pseudoviruses tested. This study demonstrates the presence of
broadly cross-neutralizing epitopes at the N-terminus of L2 that are shared by cutaneous and mucosal types and by types that infect divergent
species. BPV1 L2 was exceptionally effective at inducing cross-neutralizing antibodies to these shared epitopes.
D 2005 Elsevier Inc. All rights reserved.Keywords: Papillomavirus; Capsid protein; L2; Vaccine; Prophylactic; Neutralizing antibodyIntroduction
HPVs can be classified into those that infect non-genital
cutaneous sites and those that infect ano-genital and oral
mucosal sites (reviewed in (Lowy and Howley, 2001)).
Non-genital skin warts are a prevalent disease of child-
hood, while most ano-genital and oral infections affect
adult populations. Among the genital–mucosal genotypes,
persistent infection with ‘‘high-risk’’ or ‘‘oncogenic’’ HPV
genotypes is a necessary but not sufficient cause of
cervical cancer (Bosch et al., 1995; Clifford et al., 2003;0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.04.011
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E-mail address: roden@jhmi.edu (R.B.S. Roden).Walboomers et al., 1999). Infection with ‘‘low-risk’’ HPV
genotypes (especially HPV6 and HPV11) accounts for
most cases of genital warts. Elimination of cervical cancer
will require effective vaccination against more than 15
known genital HPV types (Bosch and de Sanjose, 2003;
Munoz et al., 2004). Protection from infection by
immunization with virus-like particles (VLPs) and by
passive transfer of antibodies in animal models (Breitburd
et al., 1995; Christensen et al., 1996b; Kirnbauer et al.,
1996; Suzich et al., 1995) have provided the rationale for
initiating vaccine trials in humans in an effort to curb the
morbidity and mortality associated with these viruses.
Immunization with VLPs composed of the Papillomavirus
(PV) major capsid protein, L1, generates neutralizing
antibodies that are primarily type specific (Christensen
and Kreider, 1990, 1991; Christensen et al., 1990; Ghim05) 365 – 372
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Roden et al., 1995). Limited cross-reactivity has been
observed among closely related types such as HPV18 and
45, and HPV6 and 11 (Christensen et al., 1994; Combita
et al., 2002; Giroglou et al., 2001; Roden et al., 1996;
White et al., 1998) when L1 or L1/L2 VLPs were the
immunogen. Furthermore, both animal challenge (Breit-
burd et al., 1995; Jarrett et al., 1990) and clinical studies
(Koutsky et al., 2002) have suggested that protection will be
largely type-specific. The plethora of oncogenic types
(notably HPV16, HPV18, HPV45, HPV31, HPV33,
HPV52 and HPV58, which together are responsible for
87% of cervical cancer cases (Munoz et al., 2004)), indicate
that broad protection will require a multi-valent vaccine
directed against as many of the >15 oncogenic HPV types as
possible. Alternative vaccination protocols yielding cross-
protective antibodies against a single antigen would greatly
reduce the complexity and expense of generating and
analyzing multi-type vaccines if they achieved similar
protection levels.
Vaccination with L2 can provide immunity from
homologous PV challenge in animal model systems. This
protection appears to be mediated by a relatively low-titer
neutralizing antibody response in vaccinated animals
(Chandrachud et al., 1995; Christensen et al., 1991;
Embers et al., 2002). In contrast to the predominantly
type-specific antibodies directed against L1 neutralization
epitopes, cross-neutralization has been observed among
divergent genital HPV types, that is, HPV6, 16 and 18
(Roden et al., 2000), or HPV6 and 16 (Kawana et al.,
1999) with antibodies generated against HPV L2 proteins
or peptides. Although they provide protection, neutralizing
antibody titers elicited by L2 vaccination are typically 2–3
orders of magnitude lower than those found in L1 VLP
vaccinated animals. Furthermore, it is unclear how
effective anti-L2 antibodies would be at neutralizing even
more distantly related papillomaviruses. Here, we study the
cross-neutralizing activity of antibodies generated against
recombinant L2 proteins and peptides from different
animal and human papillomavirus types that represent
both genital and cutaneous groups.Table 1A
Cross-neutralization of divergent human and animal papillomaviral pseudoviruses
T The bolded and shaded titers in this table represent the geometric mean neu
indicates the number of times the assay was performed.Results and discussion
Cross-neutralization of BPV1, HPV16, and HPV18
pseudoviruses with anti-full-length L2 serum
Neutralization of different papilloma pseudoviruses with
sera from rabbits immunized with L2 (full-length or
peptides) was performed. As positive and type-specificity
controls, and for inter-assay normalization of the different
papillomavirus neutralization assays, L1 VLP antiserum or
monoclonal antibodies were used; H16.V5 monoclonal for
HPV16 (Christensen et al., 1996a), 5B6 monoclonal for
BPV1 (Roden et al., 1994), or sera from rabbits immunized
with VLPs from the homologous type for the remaining
pseudoviruses. As described previously (Roden et al.,
2000), none of the sera raised against L1 or L1/L2 VLP
immunogens derived from HPV6, HPV16, HPV18, BPV1
or CRPV induced cross-neutralizing antibodies in the
pseudovirus infectivity assays tested (data not shown). This
is consistent with the presence of immuno-dominant
neutralizing epitopes in L1 and the sub-dominance of L2
in the context of the capsid (Roden et al., 2000).
Analysis of anti-full-length L2 sera was initially per-
formed with BPV1, HPV16 and HPV18 pseudoviruses. The
sera showed neutralization of the homologous types with
reciprocal titers that were 600 for BPV1; 2100 for HPV16;
and 1350 for HPV18 (Table 1A). Unlike L1 VLP antiserum,
anti-HPV18 and HPV16 full-length L2 sera showed
reciprocal cross-neutralization. These two types had been
shown to share neutralizing L2 epitope(s) (Roden et al.,
2000), and their L2 proteins share 53.4% amino acid
identity (Fig. 1). Anti-sera raised against recombinant full-
length HPV16, and HPV18 L2 protein were also able to
neutralize BPV1 pseudoviruses in this assay, albeit with
lower titers (Table 1A). In a previous study, neutralizing
activity against BPV1 pseudoviruses was not detected in the
sera of sheep immunized with these proteins (Roden et al.,
2000); however, the lack of neutralization might be
attributable to the less sensitive neutralization method used
in that study. Unexpectedly, a serum raised against full-
length BPV1 L2 neutralized HPV16 and HPV18 pseudovi-by polyclonal antisera to full-length L2 from diverse papillomaviruses
tralization titer against the homologous virus. The number in parenthesis
Fig. 1. Homology of Amino Termini of Papillomavirus L2 protein.
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HPV16 and HPV18 L2 proteins only share 38.4% or 35.7%
amino acid identity, respectively, with BPV1 L2 (Fig. 1).
Another unexpected result was the relative lack of cross-
neutralization of HPV types that are more closely related.
For example, serum against HPV31 L2, which shares 69%
identity with HPV16 and 54.3% with HPV18 (Fig. 1), only
neutralized HPV16 at a titer of 110 and did not neutralize
HPV18 at the highest concentration tested (1:50). The anti-
HPV6 L2 serum cross-neutralized HPV16 and HPV18, but
not BPV1. CRPV L2 shares 34–39% identity with BPV1,
HPV16 and HPV18 L2, and although it also unexpectedly
cross-neutralized HPV16 with relatively high titers (1350)
(Table 1A), it failed to neutralize BPV1 and HPV18.
These data together suggested that BPV1 L2 might have
an epitope(s) that is either more immunogenic or more
efficiently displayed/folded and allows for generation of
reactive, broadly cross-neutralizing anti-L2 sera. The
apparent broad cross-neutralizing activity obtained with
the full-length BPV1 L2 serum, although promising, also
generated some concerns because it was obtained from a
single animal. Immunization of another animal with the
same recombinant preparation showed similar homologous
and heterologous (HPV16) neutralization results (Table 2).
Furthermore, similar results were obtained with GST and 6-
His tagged HPV16 L2 antiserum (Table 1A), suggesting that
the tag plays no role in generating neutralizing antibodies.
Cross-neutralization of BPV1, HPV16, and HPV18
pseudoviruses with anti-L2 a.a. 1–88 serum
To map which polypeptide of the BPV1 L2 was
responsible for the cross-neutralization, sera raised against
different regions of BPV1 L2 were tested for their anti-BPV1
and HPV16 activity. The only defined cross-neutralizing
epitope described so far is for residues 108–120 of HPV16
L2 (Kawana et al., 1999). This peptide is a conserved region
in L2 with 46% identity between HPV16 and HPV18.
However, there is little homology with BPV1 L2 in this
region (15% identity). In contrast, the amino termini of L2proteins of different PV types exhibit considerably higher
percent identities, even for distantly related papillomavi-
ruses. There is 67.4% identity between HPV16 and HPV18
within the first 88 amino acids of these proteins, and both
HPV16 and HPV18 share roughly 55% identity with BPV1
L2 (Fig. 1), suggesting a conserved structure and perhaps
also function. Of note, BPV1 L2 amino acids 1–88
encompass a region that can bind to the surface of a variety
of cell lines, interfere with BPV1 infection, and may be
involved in transport of particles across the cytoplasm (Yang
et al., 2003). Furthermore, a portion of the region appears to
be displayed on BPV1 virion surfaces (a.a. 61–123) (Liu et
al., 1997). In addition, Kawana et al. (1999) showed that the
epitope of an HPV16 monoclonal antibody that neutralizes
HPV16 but not HPV6 also maps to residues 69–81. The only
two cysteines of L2 and a region very rich in glycines (Fig.
1), both with unknown function, are in this 1–88 region.
Highly conserved lysines and arginines involved in DNA
binding (Zhou et al., 1994) and infection (Roden et al., 2001)
are also in this region. The high homology in this region and
its importance in infectivity raised the possibility that an
immunogen based on a peptide from this region might induce
cross-neutralizing antibodies against divergent HPV types.
Anti-BPV1 L2 1–88 sera from two rabbits were able to
neutralize HPV16 and BPV1 pseudovirions with approx-
imately the same titers (Table 2), attesting to the reprodu-
cibility and to the ability of sera raised against the N-terminal
portion of BPV1 L2 to have good neutralizing activity
against HPV16. Anti-BPV1 L2 1–88 sera had neutralizing
titers ranging between 1780 and 4740 (Table 2), confirming
what had been seen with full-length BPV1 L2 immunization.
Furthermore, serum from a third rabbit, immunized with a
different preparation of the BPV1 L2 1–88 recombinant
protein, had similar activity (data not shown).
Cross-neutralization of native HPV11 virions by L2 a.a.
1–88 antiserum
Although BPV1 L2 1–88 antisera neutralizes BPV1
virions in the focal transformation assay (Roden et al., 1994),
Table 1B
Cross-neutralization of divergent human and animal papillomaviral
pseudovirus types by polyclonal antisera to BPV1 or HPV16 amino-
terminal L2 peptides
Anti-Serum Neutralization titera
BPV1 HPV16 HPV18 HPV31 HPV6 CRPV
BPV1 L2
a.a. 1–88
3460 (7) 4740 (7) 7020(5) 220 (3) 340 (4) 780 (3)
HPV16 L2
aa 1–88#1
<50 (4) 3080 (4) 150 (2) 260 (2) <50 (4) 260 (2)
HPV16 L2
aa 1–88#2
50 (4) 1350 (4) 150 (2) 260 (2) <50 (4) <50 (2)
HPV16 L2
aa 1–88#3
50 (4) 1780 (4) 150 (2) 90 (2) 90 (4) 260 (2)
HPV16 L2
aa 1–88#4
<50 (4) 780 (4) 90 (2) 150 (2) 60 (4) 90 (2)
a Titers are given as geometric means. The number in parenthesis
indicates the number of times the assay was performed.
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artifact of the pseudovirion system. To address this issue and
extend evidence of cross-neutralization to another HPV type,
we tested the ability of BPV1 L2 1–88 antisera to neutralize
native HPV11 in vitro (Fig. 2). Both neutralizing monoclonal
antibody H11.H3 and rabbit antiserum to full-length HPV11
L2 (1:50) completely neutralized HPV11 infection. Further-
more, a 1:50 dilution of BPV1 L2 1–88 antiserum, but not
the pre-immune serum, also neutralized native HPV11
virions. In addition to showing that BPV1 L2 1–88 can
also neutralize HPV11, this result supports the conclusion
that the neutralization data obtained with pseudovirus assay
are biologically relevant.
We sought to further define the nature of the cross-
neutralizing epitopes. An anti-BPV1 L2 45–172 serum
that had previously been shown to neutralize BPV1
(Roden et al., 1994) failed to neutralize HPV16, although
it did neutralize BPV1 in our assay at low titers. Sera
raised against peptides 130–257, 216–340, 300–425 and
384–469 failed to neutralize either BPV1 or HPV16
pseudovirus detectably (Table 2). Analysis for all experi-
ments in Tables 1A and 1B and 2 shows that rabbits
vaccinated with the L2 1–88 peptide (n = 7) do not
generate significantly higher titers against homologous
type virus than rabbits (n = 8) vaccinated with the full-
length L2 protein (P = 0.28). Our data are consistent with
the localization of the major cross-neutralizing epitopes at
the N terminus of L2. The high-titer cross-neutralizing
response obtained when immunizing with the amino
terminus of BPV1 L2 suggests that vaccination strategies
should focus on this highly conserved region.
To further define the nature of the cross-neutralizing
epitopes in HPV16 L2 recognized by BPV1 L2 1–88
antiserum, we tested its reactivity with a peptide array
comprising 20 mer peptides of the first hundred aminoFig. 2. Neutralization of native HPV11 virions by BPV1 L2 1–88
antiserum.acids of HPV16 L2 that overlapped by 12 residues.
While no single epitope was dominant, reactivity mapped
predominantly to the central region of this peptide
(Fig. 3).
We also examined sera from amino acids 1–88 of HPV16
L2 for cross-neutralizing activity. Sera from all four immu-
nized rabbits had relatively high homologous neutralization
titers (Table 1B) that ranged from 780 to 3080 and differed
by less than 4-fold. All of the anti-HPV16 L2 1–88 sera
were able to cross neutralize HPV18, but with lower titers
than those observed with the anti BPV1 L2 1–88 sera. Only
two of the four anti-HPV16 L2 1–88 sera tested were able to
neutralize BPV1 pseudoviruses at 1:50. Although the mean
titer of the anti BPV1 L2 1–88 serum appears to be higher
against the heterologous HPV16 and HPV18 pseudovirions
than against the homologous type, in each case, the median
neutralization titers are 4050, whether it is against BPV1,
HPV16 or HPV18 pseudovirus, and they do not differ more
than 3-fold from the median for each type. However, subtle
effects of differing particle to infectivity ratios between
pseudovirions preparations are also possible. The neutraliz-Table 2
Neutralization of BPV1 and HPV16 pseudoviruses by polyclonal antisera to
BPVL2 polypeptides
Anti-serum Neutralization titer
BPV1 HPV16
Pre-immune full length BPV1 L2 <50 (2) <50 (2)
Full length BPV1 L2#1 600 (4) 780 (4)
Full length BPV1 L2#2 780 (2) 780 (2)
BPV1 L2 a.a. 1–88#1 2600 (5) 1780 (4)
BPV1 L2 a.a. 1–88#2 3460 (7) 4740 (7)
BPV1 L2 a.a. 45–173 90 (4) <50 (4)
BPV1 L2 a.a. 130–257 <50 (4) <50 (4)
BPV1 L2 a.a. 216–340 <50 (2) <50 (2)
BPV1 L2 a.a. 300–425 <50 (2) <50 (2)
BPV1 L2 a.a. 384–469 <50 (2) <50 (2)
Titers are given as geometric means. The number in parenthesis indicates
the number of times the assay was performed.
Fig. 3. Reactivity of BPV1 L2 1–88 antiserum with an HPV16 L2 peptide array.
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vaccination with residues 1–88 from BPV1 (3 rabbits) and
HPV16 (4 rabbits) were not significantly different (P = 0.67).
By contrast, the neutralizing titer of antiserum to BPV1
peptide 1–88 neutralized HPV16 pseudovirus with a higher
titer than antiserum to HPV16 peptide 1–88 against BPV1
pseudovirus (P = 0.02). These results again pointed to BPV1
L2 1–88 being a better immunogen than HPV16 L2 for
eliciting cross-neutralizing HPVs.
It is possible that the neutralization titers against
homologous type virus versus heterologous type virus
might vary after repeated immunization. Therefore, we
measured the BPV1 and HPV16 pseudovirion neutralizing
titers of L2 1–88 antisera of BPV1 and HPV16 from sera
obtained 74 days (P1), 88 days (P2) and 102 days (Final)
after the initial immunization from animals that had
received 3 or 4 boosts (Table 3). Both sera demonstrated
a consistent neutralization titer against homologous type
and heterologous type virus. Thus, we find no evidence of
narrowing of BPV1 L2 1–88 antiserum specificity over
this time window and with repeated boosts.Table 3
Stability of neutralization titers with repeated immunization
Serum Bleed Boosts Day Anti
HPV16 titer
Anti
BPV1 titer
Rabbit S844-2
anti HPV16
L2 1–88
Prebleed 0 0 <50 <50
P1 3 74 4050 50
P2 4 88 4050 150
Final 4 102 4050 50
Rabbit 5315#2
anti-BPV1
L2 1–88
Prebleed 0 0 <50 <50
P1 3 74 12,150 12,150
P2 4 88 12,150 12,150
Final 4 102 12,150 12,150Cross-neutralization of HPV31, HPV6, and CRPV
pseudoviruses with anti-full-length L2 serum
Sera raised against full-length L2s were also tested
against additional pseudoviruses. The BPV1 full-length L2
sera, which had cross-neutralized HPV16 and 18 pseudo-
viruses, was unexpectedly negative against HPV31, CRPV
and HPV6 (Table 1A). HPV16 L2 shares about 69.1%
identity with HPV31, but only 53.6% and 39.4% with
HPV6 and CRPV, respectively. However, anti-HPV16 L2
sera cross-neutralized HPV31, HPV6 and CRPV, and the
titers differed by no more than 3-fold (Table 1A). HPV31 L2
shares 38.7%% identity with CRPV, an identity similar to
that between HPV16 and CRPV, but anti-HPV31 L2 was
unable to neutralize CRPV pseudoviruses. It is tempting to
attribute the lack of cross-reactivity to the relatively low
homologous titer of that serum (450); however, the
homologous BPV1 L2 titer was comparable (600), and as
noted above this serum was able to cross-neutralize HPV16
and HPV18 with similar titers (Table 1A). Anti-HPV31 full-
length L2 serum also failed to neutralize CRPV and HPV6
pseudovirions. In addition to its HPV16 cross-neutralizing
capabilities, the anti-CRPV L2 serum was also cross-
neutralizing for HPV31 and HPV6, but not for HPV18 or
BPV1, despite a similar degree of homology with these
proteins.
Cross-neutralization of HPV31, HPV6, and CRPV
pseudoviruses with anti-L2 a.a. 1–88 serum
We tested anti-BPV1 L2 a.a. 1–88 serum. Despite the
failure of anti-full-length BPV1 L2 serum to neutralize
HPV31, we found that the anti-BPV1 L2 1–88 peptide
serum was able to cross-neutralize HPV31, with titers
similar to those obtained with anti-HPV16 L2 peptide 1–88
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and HPV31 are 77% (Fig. 1), and 58% between BPV1 and
HPV31. The anti-BPV1 L2 serum was also able to
neutralize HPV6 with a titer of 340 and CRPV with a titer
of 780. Of note is the fact that the 1–88 a.a. region of BPV1
L2 has about the same amount of homology (56–58%) with
HPV16, HPV18, HPV31 and HPV6; and only slightly
lower (47.6%) with CRPV (Fig. 1).
Serum IgG is responsible for the cross-neutralizing activity
To determine whether immune IgG was responsible for
the cross-neutralization, the following two experiments were
conducted. In the first experiment, sera depleted of IgG
using protein G Sepharose was tested in HPV16 and BPV1
neutralization assays. Neither pre- nor post-immune IgG
depleted sera were able to neutralize either HPV16 or BPV1
pseudovirus (Table 4). In the second experiment, IgG from
pre- and post-immune samples were purified using protein
G columns (Pierce). Purified IgG from pre-immune sera was
unable to neutralize either pseudovirus (Table 4) at the
highest concentration tested, 1:30 (28 ng/Al), while purified
IgG from anti-BPV1 L2 1–88 serum neutralized both BPV1
and HPV16 at a dilution of 6400 (0.2 ng/Al). Purified IgG
from rabbits immunized with HPV16 L2 1–88 neutralized
both HPV16 and BPV1, but the titers were higher against
HPV16 compared to BPV1, as had been observed with
whole serum (Table 4).
Immune responses to L2 are suboptimal, since the anti-L2
neutralizing titers are significantly lower than anti-L1
neutralizing titers raised against L1 only VLPs (data not
shown); yet studies in rabbits and cattle have consistently
shown that L2 immunization can be sufficient to provide
protection, probably via neutralizing antibodies, from exper-
imental challenge with homologous virus (Campo et al.,
1997; Embers et al., 2002). Furthermore, vaccination of both
humans and mice with full-length HPV16 L2 peptides elicits
cross-neutralizing antibodies, suggesting that this phenom-
enon is not restricted by species (Kawana et al., 2001, 2003).
Taken together, the data might suggest that BPV1 L2 a.a.
1–88 constitutes an immunogen capable of generating
broad cross-neutralizing responses against both cutaneousTable 4
Cross-neutralization of BPV1 and HPV16 pseudoviruses is IgG-dependent
Anti-serum Neutralization titer
BPV1
Untreated IgG depleted Purified I
Pre-immune serum#1 <50 <50 <30 (28
Pre-immune serum#3 <50 <50 <30 (28
BPV1 L2 a.a. 1–88 4050 <50 6400 (0.2
HPV16 L2 aa 1–88#1 <50 <50 80 (10.
HPV16 L2 aa 1–88#2 50 <50 240 (4.3
HPV16 L2 aa 1–88#3 50 <50 80 (11.
HPV16 L2 aa 1–88#4 <50 <50 80 (14.
Titers are given as geometric means.and genital types, including all pseudoviruses tested to date.
Since the corresponding peptide from HPV16 failed to yield
similar results, it suggests that the BPV1 L2 immunogen in
particular may have sequences that foster re-folding of the
peptide such that a relevant cross-neutralizing epitope is
efficiently displayed. Alternatively, BPV1 L2 1–88 may
less efficiently display non-neutralizing epitopes, which
inhibit induction of antibodies to the cross-neutralizing
epitope(s). Further mapping of this region using monoclonal
antibodies would be informative as to which residues
comprise the neutralizing epitope(s), which might lead to
a broadly protective HPV L2 peptide vaccine. Indeed
vaccination of patients with the HPV16 L2 108–120
peptide generate antibody that neutralized both HPV16
and HPV52 (Kawana et al., 2003).Materials and methods
For generation of N-terminally 6-histidine tagged L2
fusion proteins, the open reading frames for L2 genes were
cloned into the pQE-12 (Qiagen) or pPro-EXHt (Invitrogen)
vectors. Full-length L2 genes included those for BPV1,
HPV16, HPV18, HPV31, HPV6 and CRPV. BPV1 His-
fusion peptides spanning the length of BPV1 L2: peptide A
(a.a. 1–88), peptide B (a.a. 45–173), peptide C (a.a. 130–
257), peptide D (a.a. 216–340), peptide E (a.a. 300–425) and
peptide F (a.a. 384–469) and full-length BPV1 L2 (a.a. 1–
469) were those described previously (Roden et al., 1994). A
similar histidine fusion peptide spanning amino acids 1–88
of HPV16 was also constructed, expressed and purified as for
the BPV1 peptides. The proteins were expressed in E. coli by
induction with IPTG, purified after being solubilized in 6 M
guanidine HCl on a Nickel agarose column (NTA from
Qiagen) and eluted at low pH (4.5) in 8 M urea. The
preparations were dialyzed overnight against PBS and stored
at 80 -C. The HPV16 L2-GST fusion protein that was
described by Roden et al. (2000), was gel-purified after
induction in E. coli. Immunization of New Zealand white
rabbits with these fusion proteins was also previously
described (Roden et al., 1994). Briefly, rabbits were primed
with aggregates of L2 protein (300 Ag) resuspended inHPV16
gG Untreated IgG depleted Purified IgG
ng/Al) <50 <50 <30 (28 ng/Al)
ng/Al) <50 <50 <30 (28 ng/Al)
ng/Al) 4050 <50 6400 (0.2 ng/Al)
4 ng/Al) 4050 <50 6400 (0.1 ng/Al)
ng/Al) 1350 <50 2130 (0.5 ng/Al)
2 ng/Al) 1350 <50 2130 (0.4 ng/Al)
1 ng/AAl) 1350 <50 710 (1.6 ng/Al)
D.V. Pastrana et al. / Virology 337 (2005) 365–372 371complete Freunds adjuvant on day 1, and boosted on days 28,
42, 60 and 76 with incomplete Freunds adjuvant. A test bleed
is taken on 56 and additional bleeds taken on 74 and 88 before
exsanguination on day 102 (Proteintech).
Maps of plasmids used for generation of high-titer
pseudoviruses are available at the website http://www.
ccr.cancer.gov/Staff/links.asp?profileid=5637. Generation
of pseudoviruses using the codon-modified L1 and L2
genes of BPV1 (plasmid pSheLL) (Buck et al., 2004; Zhou
et al., 1999), HPV16 (plasmids p16L1h and p16L2h) (Leder
et al., 2001), and HPV18 (plasmids peL1fB and peL2bhb)
(Pastrana et al., 2004) has been described previously. HPV6
and CRPV pseudoviruses were produced using expression
plasmids carrying L1 and L2 genes that were entirely
codon-modified using a previously described strategy (Buck
et al., 2004). For HPV31, it was possible to express limited
amounts of L1 and L2 using minimally codon modified
genes in the context of an expression plasmid carrying the
woodchuck hepatitis virus post-transcriptional regulatory
element (WRPE) (Donello et al., 1998).
Pseudovirions were produced as previously described
(Buck et al., 2004; Pastrana et al., 2004) with minor
modifications. Briefly, plasmids encoding L1 and L2 genes
were cotransfected into 293TT cells along with a reporter
plasmid encoding secreted alkaline phosphatase (pYSEAP)
(Pastrana et al., 2004). After 48 h, cells were lysed with
0.2% Brij-58, 9.5 mM MgCl2, 0.1–0.2% Benzonase
(Sigma) and 0.1% plasmid safe (Epicentre) and incubated
at 37 -C for 15 min. The resulting pseudovirions were then
matured by overnight incubation of the lysates at 25 -C
(BPV1, HPV16 and HPV18) or 37 -C (HPV31, CRPV, and
HPV6) overnight (Buck et al., 2005). The mature pseudovi-
rions were solubilized by addition of 0.17 volumes of 5 M
NaCl, then clarified by low speed (1500g) centrifugation.
Pseudoviruses were purified on a pre-formed 27, 33, 39%
Optiprep (Sigma) step gradient. Optiprep fractions contain-
ing SEAP-transducing activity were pooled and frozen.
Serum from individual rabbits was diluted 3-fold, with
1:50 being the highest concentration of serum tested.
Diluted sera were incubated with pseudoviruses at 4 -C
for 1 h and the combination was then used to infect 293TT
cells. The supernatants were analyzed for SEAP activity
after 72 h with the GreatEscape Chemiluminescent substrate
(BD Clontech Biosciences) on a luminometer (Dynex
Technologies). The geometric mean of the inverse neutral-
izing titer of 2–10 experiments is reported.
Neutralization assays using native HPV11 virions were
performed using Q-PCR as described in (Culp and
Christensen, 2003, 2004). Briefly, sera were maintained at
1:50 during a 1-h pre-incubation with virions and during the
entire first 48 h of infection of HaCaT cells. At 48 h, the
spent medium was removed, monolayers were rinsed with
DMEM-10 and cells were fed fresh DMEM-10 containing
H11.H3 to neutralize any virions possibly remaining at the
cell surface. RNA was harvested at 72 h p.i. The relative
expression of spliced E1^4 message was determined byreverse transcription and Q-PCR (Culp and Christensen,
2003).
For IgG depletion, 68 Al of packed Protein G sepharose
beads (Pierce) were used to absorb 60 Al of serum, and 180
Al of PBS were added to ensure proper mixing of the
sample. The samples were rocked at 4 -C for 5 h. After a
brief centrifugation, the supernatant was transferred to a
fresh tube with an additional 68 Al of beads and rocked at 4
-C overnight. The samples were centrifuged and the
supernatants used in neutralization assays.
For IgG purification, samples were purified with the
Pierce’s Nab Protein G spin purification kit, according to the
manufacturer’s recommendation.
Multiple sequence alignments were performed using the
T-Coffee computer program (Notredame et al., 2000).Acknowledgments
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